New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers

Basit Öğe Kaydı
dc.authorid0000-0003-1190-9255
dc.authorid0000-0002-4037-1979
dc.authorid0000-0002-1095-1614
dc.authorid0009-0002-1287-1308
dc.authorid0000-0002-0775-0053
dc.contributor.authorComert Onder, Ferah
dc.contributor.authorUral, Kadircan
dc.contributor.authorOnder, Alper
dc.contributor.authorOzpolat, Bulent
dc.contributor.authorAy, Mehmet
dc.date.accessioned2026-02-03T12:02:22Z
dc.date.available2026-02-03T12:02:22Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAimIn this study, new boron-containing carbamate compounds were synthesized and evaluated as potential acetylcholinesterase (AChE) inhibitors by in vitro and in silico analyses.Materials & methodsThe structures were characterized by spectroscopic analysis including 1H NMR, 13C NMR, 11B NMR, and MS. The purities of the compounds were determined by HPLC analysis. In vitro and in silico analyses were performed.ResultsBased on our findings, compounds (1-4) demonstrated more potent AChE inhibitory activity compared to tacrine, which is an FDA-approved AChE inhibitor. Compound 4 had the highest inhibitory activity with an IC50 of 37.87 +/- 0.96 nM and was more effective than tacrine (74.23 +/- 0.83 nM). Compounds 1, 2, and 3, respectively, showed 1.78-, 1.73-, and 1.58-fold more potent enzyme inhibition activity compared to tacrine. The strong interactions with critical residues in the binding pocket of AChE were identified between protein and the compounds. Furthermore, compound 4 exerted an antiproliferative activity against various human cancer cell lines (32.91 +/- 4.92 mu M in HT29 and 42.38 +/- 2.73 mu M in MCF-7).ConclusionOur study indicates the discovery of new boron-containing AChE inhibitors as potential candidates for the treatment of Alzheimer's disease and cancer.
dc.description.sponsorshipScientific and Technological Research Council of Turkiye-TUBITAK [215S008]
dc.description.sponsorshipSynthesis part of this study was supported by a research grant from the Scientific and Technological Research Council of Turkiye-TUBITAK (Grant No. 215S008).
dc.identifier.doi10.1080/17568919.2025.2525065
dc.identifier.endpage1389
dc.identifier.issn1756-8919
dc.identifier.issn1756-8927
dc.identifier.issue12
dc.identifier.pmid40600330
dc.identifier.scopus2-s2.0-105009737752
dc.identifier.scopusqualityQ2
dc.identifier.startpage1377
dc.identifier.urihttps://doi.org/10.1080/17568919.2025.2525065
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34729
dc.identifier.volume17
dc.identifier.wosWOS:001521865500001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofFuture Medicinal Chemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectBoron
dc.subjectAlzheimer's disease
dc.subjectAChE
dc.subjectanticancer
dc.subjectMD simulation
dc.titleNew and potential boron-containing compounds for treatment of Alzheimer's disease and cancers
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu